Jaguar Health Inc (JAGX) Stock Price, Quote & News

Latest News on JAGX

Apr 17, 2025, 9:00 AM EDT - 8 days ago

Proof-of-Concept Data for Rare Disease Indications MVID and SBS-IF for Jaguar Health's Crofelemer to be Presented at April 2025 ELITE PED-GI Congress

Apr 15, 2025, 9:30 AM EDT - 10 days ago

Jaguar Health Announces Significant Results in Breast Cancer Patients Accepted for Presentation at Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting

Apr 8, 2025, 8:30 AM EDT - 17 days ago

Napo Pharmaceuticals, a Jaguar Health Family Company, Exhibiting at the Oncology Nursing Society (ONS) Congress for the FDA-Approved Gelclair Oral Mucositis Prescription Product

Apr 4, 2025, 4:15 PM EDT - 21 days ago

Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 1, 2025, 4:15 PM EDT - 24 days ago

Jaguar Health Announces Closing of Bridge Financing Priced At-The-Market Under Nasdaq Rules

Mar 31, 2025, 9:57 AM EDT - 25 days ago

Jaguar Health, Inc. (JAGX) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 8:00 AM EDT - 25 days ago

Jaguar Health Reports 2024 Financials: 2024 Net Revenue Up Approximately 20% Over 2023

Mar 28, 2025, 9:00 AM EDT - 4 weeks ago

83.33% of Veterinary Oncologists Highlight Importance of Jaguar Health's FDA Conditionally Approved Canalevia-CA1 as a Non-Antibiotic Treatment for Chemotherapy-Induced Diarrhea (CID) in Dog's in New Survey

Mar 27, 2025, 8:30 AM EDT - 4 weeks ago

Jaguar Health Meeting with FDA Regarding Results of Phase 3 OnTarget Study

Mar 26, 2025, 11:00 AM EDT - 4 weeks ago

Jaguar Health Presenting March 27 at Emerging Growth Conference and Holding Investor Webcast March 31 Regarding Q4 2024 Financials & Near-Term Catalysts

Mar 26, 2025, 9:25 AM EDT - 4 weeks ago

Jaguar Health CEO, Board Members, Other C-Suite Members, and Institutional and Accredited Investors Invest in $3.448 Million Bridge Financing Priced At-The-Market Under Nasdaq Rules

Mar 18, 2025, 8:30 AM EDT - 5 weeks ago

Jaguar Health, Inc. Announces Reverse Stock Split

Mar 13, 2025, 4:15 PM EDT - 6 weeks ago

Jaguar Health Reports Approval of All Proposals at March 2025 Special Meeting of Stockholders

Feb 27, 2025, 8:30 AM EST - 2 months ago

Jaguar Health Adopts Limited Duration Stockholder Rights Plan to Ensure Stockholders Can Realize Long-Term Value

Feb 19, 2025, 9:00 AM EST - 2 months ago

Jaguar Receives Regulatory Clearance in Germany and Italy for Crofelemer for Rare Disease Study - Short Bowel Syndrome with Intestinal Failure (SBS-IF)

Feb 18, 2025, 9:00 AM EST - 2 months ago

Jaguar Health Extends Collaboration for Possible Tropical Disease Priority Review Voucher and Cholera Indication for NP-300

Feb 13, 2025, 9:05 AM EST - 2 months ago

Jaguar Health Presenting February 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts

Feb 6, 2025, 10:00 AM EST - 2 months ago

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present February 10th at BIO CEO & Investor Conference

Feb 3, 2025, 9:30 AM EST - 2 months ago

Jaguar Health Announces First Patient Dosed in Short Bowel Syndrome with Intestinal Failure in Investigator-Initiated Trial of Crofelemer; Proof-of-Concept Data Potentially Available H1 2025

Jan 29, 2025, 8:30 AM EST - 3 months ago

Jaguar Health Supports Evaluation of FDA-Approved Crofelemer to Address GI Side Effects of GLP-1 and Other Weight Loss Therapies: Files Patent Application with USPTO

Jan 22, 2025, 9:00 AM EST - 3 months ago

Jaguar Health Announces First Patient Dosed in Investigator-Initiated Trial (IIT) Evaluating Crofelemer for the Rare Disease Indication of Microvillus Inclusion Disease (MVID), with Proof-of-Concept (POC) Data Potentially Available H1 2025

Jan 8, 2025, 8:30 AM EST - 3 months ago

Jaguar Health Presenting January 13 at Lytham 2025 Investor Healthcare Summit & January 14 at Biotech Showcase

Jan 7, 2025, 10:00 AM EST - 3 months ago

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present January 12 at the Annual Neuroscience Innovation Forum

Dec 19, 2024, 9:00 AM EST - 4 months ago

Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating Mental Health Indications

Dec 18, 2024, 10:00 AM EST - 4 months ago

Phase 2 Study Initiated to Evaluate Jaguar Health's Crofelemer for Microvillus Inclusion Disease (MVID), an Ultrarare Congenital Diarrheal Disorder

Dec 17, 2024, 8:30 AM EST - 4 months ago

FDA Approves Orphan-Drug Designation for Jaguar Health's Crofelemer for Treatment of Diarrhea in Cholera

Dec 13, 2024, 10:00 AM EST - 4 months ago

Ladenburg Thalmann to Host Scientific Showcase December 18, 2024 About Rare Disease Clinical Development Efforts for Jaguar Health's Crofelemer

Dec 12, 2024, 9:00 AM EST - 4 months ago

Significant Positive Results with Jaguar Health's Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients Presented at San Antonio Breast Cancer Symposium (SABCS)

Dec 9, 2024, 10:00 AM EST - 4 months ago

Poster Presentation Describing the Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients to Take Place December 11, 2024 at San Antonio Breast Cancer Symposium (SABCS)

Dec 6, 2024, 8:30 AM EST - 5 months ago

U.S. Investigator-Initiated Trial (IIT) to Evaluate Jaguar Health's Crofelemer for Short Bowel Syndrome with Intestinal Failure (SBS-IF) Begins

Dec 5, 2024, 12:00 PM EST - 5 months ago

Article about Canalevia-CA1, Jaguar Health's Prescription Drug Conditionally Approved by the FDA for the Treatment of Chemotherapy-Induced Diarrhea in Dogs, Published in PetVet Magazine

Dec 2, 2024, 10:00 AM EST - 5 months ago

Jaguar Health Participating in December 3-5 Pet Connect Conference with Goal of Identifying Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs

Nov 25, 2024, 10:00 AM EST - 5 months ago

Jaguar Health Presenting December 3rd at NobleCon20 and December 5th at the Emerging Growth Conference

Nov 22, 2024, 8:45 AM EST - 5 months ago

Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs

Nov 19, 2024, 9:30 AM EST - 5 months ago

Jaguar Health Family Company Napo Therapeutics Named “Best Pharmaceuticals Innovator of the Year - Europe”

Nov 15, 2024, 2:47 PM EST - 5 months ago

Jaguar Health, Inc. (JAGX) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 8:00 AM EST - 5 months ago

Jaguar Health Reports Third Quarter 2024 Financial Results

Nov 11, 2024, 8:30 AM EST - 5 months ago

Jaguar Health to Hold Investor Webcast Wednesday, November 13th at 8:30 AM Eastern Regarding Q3 2024 Financials & Corporate Updates

Nov 6, 2024, 10:00 AM EST - 6 months ago

FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea in Dogs

Nov 4, 2024, 8:30 AM EST - 6 months ago

Abstract Describing Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea in Breast Cancer Patients Accepted for Presentation at San Antonio Breast Cancer Symposium (SABCS)

$Significant Positive Results with Jaguar Health's Crofelemer for Chronic Refractory Diarrhea in IBS-D, Presented at American College of Gastroenterology Annual Meeting$

Oct 29, 2024, 10:00 AM EDT - 6 months ago

Significant Positive Results with Jaguar Health's Crofelemer for Chronic Refractory Diarrhea in IBS-D, Presented at American College of Gastroenterology Annual Meeting

Oct 16, 2024, 11:00 AM EDT - 6 months ago

Small-cap biotech Jaguar Health's stock jumps 7% as it launches treatment for oral mucositis in cancer patients

Oct 16, 2024, 8:30 AM EDT - 6 months ago

Jaguar Health Launches FDA-Approved Oral Mucositis Prescription Product Gelclair in the U.S.

Oct 10, 2024, 10:00 AM EDT - 7 months ago

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present October 16 at BIO Investor Forum

Oct 8, 2024, 8:30 AM EDT - 7 months ago

Jaguar Health Submits Abstract for First-of-Kind Study Evaluating the Impact of Diarrhea from Cancer Therapies in Breast Cancer Patients Who Received Placebo in its OnTarget Phase 3 Trial

Oct 1, 2024, 8:30 AM EDT - 7 months ago

Jaguar Health Reports Statistically Significant Improvement in Breast Cancer Patients in its Phase 3 OnTarget Trial for its Cancer Supportive Care Drug Crofelemer

Sep 26, 2024, 10:00 AM EDT - 7 months ago

Jaguar Health Scientific Advisory Board Member to Share Poster Presentation at American Society of Clinical Oncology (ASCO) Quality Care Symposium About the Methodologies Involved in Designing an Advocate-Led Quality of Life Survey for Cancer Patients and Survivors

Sep 25, 2024, 8:30 AM EDT - 7 months ago

Jaguar Health to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024

Sep 24, 2024, 10:00 AM EDT - 7 months ago

Jaguar Health to Spotlight Company's Commercial Focus on Cancer Supportive Care at American Society for Radiation Oncology (ASTRO) Annual Meeting for FDA-Approved Gelclair Oral Mucositis Product in Advance of October 2024 Gelclair Launch

Sep 16, 2024, 10:00 AM EDT - 7 months ago

Market Cap	5.43M
Revenue (ttm)	11.69M
Net Income (ttm)	-38.49M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-329.26%
Debt to Equity Ratio	3.62

Volume	2,977,000
Avg Vol	104,581
Day's Range	N/A - N/A
Shares Out	674,000.00
Stochastic %K	56%
Beta	1.10
Analysts	Strong Sell
Price Target	$150.00